HUP0200493A3 - Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseases - Google Patents
Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseasesInfo
- Publication number
- HUP0200493A3 HUP0200493A3 HU0200493A HUP0200493A HUP0200493A3 HU P0200493 A3 HUP0200493 A3 HU P0200493A3 HU 0200493 A HU0200493 A HU 0200493A HU P0200493 A HUP0200493 A HU P0200493A HU P0200493 A3 HUP0200493 A3 HU P0200493A3
- Authority
- HU
- Hungary
- Prior art keywords
- sulphonyl
- kappa
- amino
- treatment
- pharmaceutical compositions
- Prior art date
Links
- 102000003945 NF-kappa B Human genes 0.000 title 1
- 108010057466 NF-kappa B Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 sulphonyl-amino-carbonyl Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26820301P | 2001-02-12 | 2001-02-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0200493D0 HU0200493D0 (en) | 2002-04-29 |
HUP0200493A2 HUP0200493A2 (en) | 2002-10-28 |
HUP0200493A3 true HUP0200493A3 (en) | 2003-04-28 |
Family
ID=23021923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0200493A HUP0200493A3 (en) | 2001-02-12 | 2002-02-11 | Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseases |
Country Status (11)
Country | Link |
---|---|
US (1) | US20020183384A1 (hu) |
EP (1) | EP1236468A1 (hu) |
JP (1) | JP2002275062A (hu) |
KR (1) | KR20020067011A (hu) |
CN (1) | CN1370526A (hu) |
AU (1) | AU1539402A (hu) |
CA (1) | CA2369967A1 (hu) |
HU (1) | HUP0200493A3 (hu) |
IL (1) | IL148034A0 (hu) |
NZ (1) | NZ517021A (hu) |
ZA (1) | ZA200201161B (hu) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
GB0325192D0 (en) * | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
WO2005099686A1 (ja) * | 2004-04-07 | 2005-10-27 | Fujicco Co., Ltd. | カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物 |
NZ587106A (en) * | 2004-12-14 | 2012-03-30 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
US7749997B2 (en) | 2005-12-22 | 2010-07-06 | Astrazeneca Ab | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors |
CA2651663A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Chemical compounds |
US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
JP2009539818A (ja) * | 2006-06-08 | 2009-11-19 | アストラゼネカ アクチボラグ | ベンゾイミダゾールおよび糖尿病の処置のためのその使用 |
KR100842351B1 (ko) * | 2007-01-04 | 2008-06-30 | 한국생명공학연구원 | 인돌 유도체를 유효성분으로 함유하는 암 예방 및 치료용약학적 조성물 |
AU2008290327A1 (en) * | 2007-08-17 | 2009-02-26 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
KR20100099738A (ko) | 2007-12-20 | 2010-09-13 | 아스트라제네카 아베 | Dgat1 억제제로서의 카르바모일 화합물 190 |
MX2011006672A (es) * | 2008-12-19 | 2011-07-20 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes. |
US9339524B2 (en) | 2009-03-11 | 2016-05-17 | Jellice Co., Ltd. | Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food |
BRPI1016109A2 (pt) | 2009-06-19 | 2016-05-17 | Astrazeneca Ab | "composto, composição farmacêutica, e, processo para preparar um composto" |
CN103040815B (zh) * | 2011-10-13 | 2014-12-10 | 中国科学院上海药物研究所 | 一类2,4,6-三异丙基苯类化合物在制备治疗糖尿病的药物中的用途 |
MD3259253T2 (ro) * | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
KR20180004242A (ko) * | 2015-05-08 | 2018-01-10 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 알쯔하이머병의 치료를 위한 뉴런 저장소-작동된 칼슘 진입 경로의 활성화 |
US11858922B2 (en) | 2016-02-16 | 2024-01-02 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
EP3872070A1 (en) * | 2016-04-18 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
TWI789401B (zh) | 2017-07-07 | 2023-01-11 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
CU24615B1 (es) | 2017-07-24 | 2022-07-08 | Novartis Ag | Compuestos para tratar afecciones asociadas con la actividad nlrp |
BR112020002906A2 (pt) | 2017-08-15 | 2020-08-04 | Inflazome Limited | novos compostos de sulfonamida-carboxamida |
UY37848A (es) * | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
WO2019034697A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
UY37847A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
RU2020110366A (ru) * | 2017-08-15 | 2021-09-16 | Инфлазоум Лимитед | Новые соединения сульфонамидкарбоксамидов |
CN111315733A (zh) * | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
EP3759073A1 (en) * | 2018-03-02 | 2021-01-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1449404A (en) * | 1973-03-30 | 1976-09-15 | Science Union & Cie | N-arylsulphonyl urea derivatives |
US5194588A (en) * | 1985-01-22 | 1993-03-16 | Ici Americas Inc. | Aminoalcohol intermediates for peptide derivatives |
US5245068A (en) * | 1990-10-30 | 1993-09-14 | Warner-Lambert Company | Oxysulfonyl carbamates |
US5254715A (en) * | 1990-11-07 | 1993-10-19 | Warner-Lambert Company | Aminosulfonyl carbamates |
US5214206A (en) * | 1990-11-07 | 1993-05-25 | Warner-Lambert Company | Aminosulfonyl urea acat inhibitors |
US5198466A (en) * | 1990-11-09 | 1993-03-30 | Warner-Lambert Company | Oxysulfonyl urea acat inhibitors |
US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
IL109431A (en) * | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
IL122247A0 (en) * | 1995-08-04 | 1998-04-05 | Warner Lambert Co | Use of sulfamic acid derivatives acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels |
GEP20001898B (en) * | 1995-11-02 | 2000-01-05 | Warner Lambert Co | Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam |
US5948886A (en) * | 1996-11-20 | 1999-09-07 | Hoechst Marion Roussel, Inc. | Acylated enol derivatives of α-ketoesters and α-ketoamides |
AU2738897A (en) * | 1996-05-17 | 1997-12-09 | Warner-Lambert Company | N-acyl sulfamic acid esters useful as hypocholesterolemic agents |
ATE242208T1 (de) * | 1997-01-29 | 2003-06-15 | Pfizer | Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität |
US6093744A (en) * | 1997-04-21 | 2000-07-25 | Warner-Lambert Company | N-acyl sulfamic acid esters useful as hypocholesterolemic agents |
CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
DK1145717T3 (da) * | 2000-04-13 | 2004-08-02 | Pfizer Prod Inc | Synergistisk virkning af glyburid og milrinon |
-
2002
- 2002-02-01 CA CA002369967A patent/CA2369967A1/en not_active Abandoned
- 2002-02-04 AU AU15394/02A patent/AU1539402A/en not_active Abandoned
- 2002-02-04 NZ NZ517021A patent/NZ517021A/en unknown
- 2002-02-05 EP EP02002612A patent/EP1236468A1/en not_active Withdrawn
- 2002-02-06 IL IL14803402A patent/IL148034A0/xx unknown
- 2002-02-08 US US10/071,034 patent/US20020183384A1/en not_active Abandoned
- 2002-02-08 JP JP2002032755A patent/JP2002275062A/ja active Pending
- 2002-02-09 KR KR1020020007716A patent/KR20020067011A/ko not_active Application Discontinuation
- 2002-02-10 CN CN02104763A patent/CN1370526A/zh active Pending
- 2002-02-11 HU HU0200493A patent/HUP0200493A3/hu unknown
- 2002-02-11 ZA ZA200201161A patent/ZA200201161B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0200493A2 (en) | 2002-10-28 |
HU0200493D0 (en) | 2002-04-29 |
CN1370526A (zh) | 2002-09-25 |
IL148034A0 (en) | 2002-09-12 |
AU1539402A (en) | 2002-08-15 |
ZA200201161B (en) | 2003-08-11 |
NZ517021A (en) | 2003-09-26 |
JP2002275062A (ja) | 2002-09-25 |
EP1236468A1 (en) | 2002-09-04 |
KR20020067011A (ko) | 2002-08-21 |
CA2369967A1 (en) | 2002-08-12 |
US20020183384A1 (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0200493A2 (en) | Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseases | |
HUP0401514A3 (en) | Pharmaceutical compositions for the treatment of asthma | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
PL362711A1 (en) | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | |
IL145470A0 (en) | Compositions for the treatment of immune diseases | |
IL169338A0 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
IL161070A0 (en) | Compositions for the treatment of infectious diseases | |
NO324227B1 (no) | Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer | |
IL157734A0 (en) | Pharmaceutical compositions for the treatment of urogenital disorders | |
HUP0600781A2 (en) | Compounds for the treatment of metabolic disorders and pharmaceutical compositions containing them | |
HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
IL164896A (en) | Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors | |
AU2002210385A1 (en) | Furazanyl-triazole derivates for the treatment of diseases | |
AU2002240359A1 (en) | Pharmaceutical composition for the treatment of alopecia | |
HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
PT1446107E (pt) | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso | |
HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
AU2002322082A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
AU2002325169A1 (en) | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | |
IL160852A0 (en) | Pharmaceutical compositions for the treatment of urinary disorders | |
IL137275A0 (en) | Pharmaceutical composition for the treatment of anal fissures | |
GB0028484D0 (en) | Imidazolone derivatives for the treatment of viral diseases | |
HUP0200253A2 (en) | Pharmaceutical compositions for combination therapy | |
EP1458403A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT AND CLINICAL REMISSION OF PSORIASIS | |
HUP0301971A3 (en) | Uses of thaliporphine or its derivatives for producing pharmaceutical compositions suitable for treating cardiac diseases and the compounds |